|Back to main|
Good News for Nymox's Pipeline - Analyst Blog
Positive news flowed in at
Nymox Pharmaceutical Corporation
) recently when the Independent Data Monitoring Committee (IDMC)
reported the third positive analysis of safety data from the
company's ongoing phase II study (NX03-0040) of NX-1207 for low
grade localized prostate cancer.
The IDMC's interim safety analysis found no significant safety concerns associated with the use of NX-1207 for the treatment of low risk localized prostate cancer. The NX03-0040 study is assessing the efficacy and safety of both low (2.5 mg) and high (15 mg) single doses of NX-1207 in eradicating or shrinking low grade localized prostate cancer tumors. The phase II study is ongoing and is expected to be completed by May 2013.
NX-1207 is in phase III development both in the US and Europe for the treatment of patients suffering from benign prostatic hyperplasia (BPH). In Europe, the company has a licensing agreement with Recordati S.p.A. Recordati is sponsoring the recently initiated phase III study in Europe.
We note that the prostrate cancer market offers a lucrative opportunity. Currently approved prostate cancer treatments include Johnson & Johnson 's ( JNJ ) Zytiga. Moreover, the prostate cancer market saw a new entrant in Aug 2012 in the form of Medivation 's ( MDVN ) Xtandi (enzalutamide).
Nymox Pharma currently carries a Zacks Rank #3 (Hold). Stocks that currently look attractive in the pharma space include companies like Cytokinetics, Inc. ( CYTK ) carrying a Zacks Rank #1 (Strong Buy).
CYTOKINETCS INC (CYTK): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
MEDIVATION INC (MDVN): Free Stock Analysis Report
NYMOX PHARMACTL (NYMX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research